Christian Frerker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Frerker has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
Tobias Schmidt
6 shared publications- Tobias Schmidt
Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany
6 shared publications - Ingo Eitel
University Heart Center Lübeck, Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Hospital Schleswig-Holstein, Lübeck, Germany
5 shared publications Christoph Marquetand
3 shared publications- Christoph Marquetand
Department for Cardiology, Angiology and Intensive Care Medicine, University Clinic Schleswig-Holstein and University Heart Center Luebeck, Luebeck, Germany
3 shared publications - Karl-Heinz Kuck
University Heart Centre Lübeck, Department of Rhythmology, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, Campus Lübeck 23538, Germany
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
First Experience of a New Transfemoral Transcatheter Mitral Valve Replacement System
- 23 October 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
Open AccessFirst Experience of a New Transfemoral Transcatheter Mitral Valve Replacement System
- 7 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 521-526
The Frontier V Study: Evaluating the Safety and Clinical Performance of a Large‐Bore Vascular Closure Device After Femoral Arterial Access
Background: Vascular complications following large‐bore procedures may have a significant impact on patient morbidity and mortality, highlighting the critical need for an effective, safe, and reproducible closure device. We present our prospective multi‐center experience with a novel patch‐based closure device. Aim: To evaluate the safety and clinical performance of the PerQseal+ closure system in achieving hemostasis after femoral arterial large‐bore access with 14–22 F sheaths. Methods: The Frontier V study (NCT04799769) is a multicenter study that included patients undergoing an endovascular procedure requiring femoral access created by 14−22 F sheaths. The primary safety outcome was major access site complications related to the PerQseal+. The primary efficacy outcome was the technical success rate of device deployment. Secondary outcomes included minor access site complications related to the device, time to hemostasia, time to deployment, and time to total closure. Results: A total of 88 subjects were included at seven investigational centers in Europe. One device‐related major access site complication (i.e., retroperitoneal hematoma) occurred (1.1%). The acute success rate of device deployment was 95%. There were five minor vascular access site complications directly related to the device (5.7%). The median time of device deployment was 5 min, the median time to achieve hemostasia was 1 min, and the median total closure time was 6 min. Conclusion: The PerQseal+ closure device was safe and effective for large‐bore arterial femoral closure. These results highlight its potential as a reliable alternative for large‐bore closure in endovascular procedures.
- 7 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 521-526
The Frontier V Study: Evaluating the Safety and Clinical Performance of a Large‐Bore Vascular Closure Device After Femoral Arterial Access
Background: Vascular complications following large‐bore procedures may have a significant impact on patient morbidity and mortality, highlighting the critical need for an effective, safe, and reproducible closure device. We present our prospective multi‐center experience with a novel patch‐based closure device. Aim: To evaluate the safety and clinical performance of the PerQseal+ closure system in achieving hemostasis after femoral arterial large‐bore access with 14–22 F sheaths. Methods: The Frontier V study (NCT04799769) is a multicenter study that included patients undergoing an endovascular procedure requiring femoral access created by 14−22 F sheaths. The primary safety outcome was major access site complications related to the PerQseal+. The primary efficacy outcome was the technical success rate of device deployment. Secondary outcomes included minor access site complications related to the device, time to hemostasia, time to deployment, and time to total closure. Results: A total of 88 subjects were included at seven investigational centers in Europe. One device‐related major access site complication (i.e., retroperitoneal hematoma) occurred (1.1%). The acute success rate of device deployment was 95%. There were five minor vascular access site complications directly related to the device (5.7%). The median time of device deployment was 5 min, the median time to achieve hemostasia was 1 min, and the median total closure time was 6 min. Conclusion: The PerQseal+ closure device was safe and effective for large‐bore arterial femoral closure. These results highlight its potential as a reliable alternative for large‐bore closure in endovascular procedures.
- Open Access
- 15 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (8) , e040435
Invasive Strategy With Intended Percutaneous Coronary Intervention Versus Conservative Treatment in Older People With ST‐Segment–Elevation Myocardial Infarction: A Meta‐Analysis
Background: Patients ≥80 years old were underrepresented or excluded from landmark trials demonstrating the superiority of primary percutaneous coronary intervention (PCI) in ST‐segment–elevation myocardial infarction. The current meta‐analysis assessed the effects of an invasive strategy with intended PCI compared with conservative treatment in older people (≥80 years) with ST‐segment–elevation myocardial infarction. Methods: A structured literature search was performed. The primary outcome was overall survival. Secondary outcome analyses included but were not limited to 30‐day and 1‐year mortality. Results: Thirteen studies reporting on 102 158 older adults were included. Of these, 31 629 (31%) were assigned to PCI and 70 529 (69%) were treated conservatively. The overall survival was 76.5% in PCI and 67.2% in conservative treatment at the time of longest available follow‐up (odds ratio [OR], 2.18 [95% CI, 1.79–2.66], P I 2 =88%, favoring PCI). The follow‐up period ranged from 30 days to 26.5 months. The 30‐day. (OR, 0.39 [95% CI, 0.31–0.50], P I 2 =0%) and 1‐year mortality (OR, 0·34 [95% CI, 0.25–0.46], P I 2 =0%), were lower in the PCI group. Conclusions: This meta‐analysis indicates a potential underuse of PCI in older adults with ST‐segment–elevation myocardial infarction. PCI was advantageous in short‐ and long‐term survival, but these results were affected by confounding. Nonetheless, every second patient not referred for invasive treatment survived at least 1 year. These findings have hypothesis generating implications, but they indicate ageism and emphasize that PCI should not be automatically withheld in older patients.
- 15 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (8) , e040435
Open AccessInvasive Strategy With Intended Percutaneous Coronary Intervention Versus Conservative Treatment in Older People With ST‐Segment–Elevation Myocardial Infarction: A Meta‐Analysis
Background: Patients ≥80 years old were underrepresented or excluded from landmark trials demonstrating the superiority of primary percutaneous coronary intervention (PCI) in ST‐segment–elevation myocardial infarction. The current meta‐analysis assessed the effects of an invasive strategy with intended PCI compared with conservative treatment in older people (≥80 years) with ST‐segment–elevation myocardial infarction. Methods: A structured literature search was performed. The primary outcome was overall survival. Secondary outcome analyses included but were not limited to 30‐day and 1‐year mortality. Results: Thirteen studies reporting on 102 158 older adults were included. Of these, 31 629 (31%) were assigned to PCI and 70 529 (69%) were treated conservatively. The overall survival was 76.5% in PCI and 67.2% in conservative treatment at the time of longest available follow‐up (odds ratio [OR], 2.18 [95% CI, 1.79–2.66], P I 2 =88%, favoring PCI). The follow‐up period ranged from 30 days to 26.5 months. The 30‐day. (OR, 0.39 [95% CI, 0.31–0.50], P I 2 =0%) and 1‐year mortality (OR, 0·34 [95% CI, 0.25–0.46], P I 2 =0%), were lower in the PCI group. Conclusions: This meta‐analysis indicates a potential underuse of PCI in older adults with ST‐segment–elevation myocardial infarction. PCI was advantageous in short‐ and long‐term survival, but these results were affected by confounding. Nonetheless, every second patient not referred for invasive treatment survived at least 1 year. These findings have hypothesis generating implications, but they indicate ageism and emphasize that PCI should not be automatically withheld in older patients.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e038834
Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study
Background: Mitral valve transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a viable therapy option in patients with severe mitral regurgitation and high surgical risk. Although atrial fibrillation is common among patients undergoing M‐TEER, the optimal anticoagulatory treatment after the intervention is unknown. Methods: A single‐center retrospective observational analysis was conducted using data from the M‐TEER registry at the University Hospital Cologne collected from 2019 untill 2021 including patients undergoing M‐TEER between November 2012 and April 2019. Patients with atrial fibrillation receiving consistent anticoagulation following M‐TEER were categorized into a direct oral anticoagulant or a vitamin K antagonist (VKA) group. The primary end point was a composite of ischemic cerebrovascular and bleeding events. Additionally, overall survival was assessed. Results: Among 613 patients undergoing M‐TEER, 206 met the inclusion criteria, with 61 receiving direct oral anticoagulants and 145 receiving VKAs. After a median follow‐up of 833 (interquartile range, 355–1271) days, the incidence of the composite primary end point did not differ between direct oral anticoagulant and VKA groups (hazard ratio [HR], 0.51 [95% CI, 0.23–1.12]; P =0.07). Similarly, rates of ischemic cerebrovascular events and bleeding events were similar between groups. However, the overall mortality rate was higher in the VKA group (HR, 2.56 [95% CI, 1.54–4.26]; P =0.002). In the multivariable analysis, oral anticoagulation with a VKA was an independent predictor for death (adjusted HR, 2.23 [95% CI, 1.08–5.06]; P =0.03). Conclusions: Our findings suggest that direct oral anticoagulants may offer comparable efficacy and safety to VKAs in preventing thromboembolic events following M‐TEER in patients with atrial fibrillation. Further randomized trials are needed to confirm these results and establish optimal anticoagulation strategies in this patient population.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e038834
Open AccessDirect Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study
Background: Mitral valve transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a viable therapy option in patients with severe mitral regurgitation and high surgical risk. Although atrial fibrillation is common among patients undergoing M‐TEER, the optimal anticoagulatory treatment after the intervention is unknown. Methods: A single‐center retrospective observational analysis was conducted using data from the M‐TEER registry at the University Hospital Cologne collected from 2019 untill 2021 including patients undergoing M‐TEER between November 2012 and April 2019. Patients with atrial fibrillation receiving consistent anticoagulation following M‐TEER were categorized into a direct oral anticoagulant or a vitamin K antagonist (VKA) group. The primary end point was a composite of ischemic cerebrovascular and bleeding events. Additionally, overall survival was assessed. Results: Among 613 patients undergoing M‐TEER, 206 met the inclusion criteria, with 61 receiving direct oral anticoagulants and 145 receiving VKAs. After a median follow‐up of 833 (interquartile range, 355–1271) days, the incidence of the composite primary end point did not differ between direct oral anticoagulant and VKA groups (hazard ratio [HR], 0.51 [95% CI, 0.23–1.12]; P =0.07). Similarly, rates of ischemic cerebrovascular events and bleeding events were similar between groups. However, the overall mortality rate was higher in the VKA group (HR, 2.56 [95% CI, 1.54–4.26]; P =0.002). In the multivariable analysis, oral anticoagulation with a VKA was an independent predictor for death (adjusted HR, 2.23 [95% CI, 1.08–5.06]; P =0.03). Conclusions: Our findings suggest that direct oral anticoagulants may offer comparable efficacy and safety to VKAs in preventing thromboembolic events following M‐TEER in patients with atrial fibrillation. Further randomized trials are needed to confirm these results and establish optimal anticoagulation strategies in this patient population.
- Open Access
- 1 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (2) , ytaf066
Successful implantation of an EVOQUE-tricuspid valve replacement system in a patient with two right ventricular implantable cardioverter-defibrillator leads: a case report
Background: Tricuspid regurgitation (TR) is a disease with significant morbidity and mortality rates. Besides surgery and transcatheter edge-to-edge repair (TEER), transcatheter tricuspid valve replacement has evolved as a possible treatment option in high-risk patients with an unfavourable anatomy for TEER. Case summary: We present a case of an 82-year-old patient with torrential TR due to an annulus dilation and subsequent central gap of >8 mm. Echocardiographic guiding was impeded by the presence of two permanent right ventricular implantable cardioverter-defibrillator (ICD) leads and previous surgical aortic valve implantation and mitral valve reconstruction. An EVOQUE prosthesis (Edwards Lifesciences; Irvine, USA) was successfully implanted without impairment of the ICD function or significant paravalvular leakage. Conclusion: Transcatheter tricuspid valve replacement with the EVOQUE-tricuspid valve replacement system is feasible even in patients with two right ventricular ICD leads and limited echocardiographic visibility.
- 1 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (2) , ytaf066
Open AccessSuccessful implantation of an EVOQUE-tricuspid valve replacement system in a patient with two right ventricular implantable cardioverter-defibrillator leads: a case report
Background: Tricuspid regurgitation (TR) is a disease with significant morbidity and mortality rates. Besides surgery and transcatheter edge-to-edge repair (TEER), transcatheter tricuspid valve replacement has evolved as a possible treatment option in high-risk patients with an unfavourable anatomy for TEER. Case summary: We present a case of an 82-year-old patient with torrential TR due to an annulus dilation and subsequent central gap of >8 mm. Echocardiographic guiding was impeded by the presence of two permanent right ventricular implantable cardioverter-defibrillator (ICD) leads and previous surgical aortic valve implantation and mitral valve reconstruction. An EVOQUE prosthesis (Edwards Lifesciences; Irvine, USA) was successfully implanted without impairment of the ICD function or significant paravalvular leakage. Conclusion: Transcatheter tricuspid valve replacement with the EVOQUE-tricuspid valve replacement system is feasible even in patients with two right ventricular ICD leads and limited echocardiographic visibility.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (47) , 5058-5067
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial
Background and Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C). Methods: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711. Results: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size assessed by CMR imaging was similar in both study groups [25.4% of LV mass (%LV) vs. 25.2%LV; P = .386]. However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; P = .017) and the extent of MVO (2.1%LV vs. 3.4%LV; P = .025) were significantly reduced in the GP IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non–life-threatening bleedings (22.6% vs. 6.9%; P = .016) without differences in all-cause mortality (4.8% vs. 3.4%; P = .703). Conclusions: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (47) , 5058-5067
Open AccessGlycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial
Background and Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C). Methods: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711. Results: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size assessed by CMR imaging was similar in both study groups [25.4% of LV mass (%LV) vs. 25.2%LV; P = .386]. However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; P = .017) and the extent of MVO (2.1%LV vs. 3.4%LV; P = .025) were significantly reduced in the GP IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non–life-threatening bleedings (22.6% vs. 6.9%; P = .016) without differences in all-cause mortality (4.8% vs. 3.4%; P = .703). Conclusions: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.
- Open Access
- 31 July 2024
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 87, 121-132
Comparison of different venous access ways for right heart catheterization—a meta-analysis
- 31 July 2024
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 87, 121-132
Open AccessComparison of different venous access ways for right heart catheterization—a meta-analysis
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2024 (1)
Predictors for Sedation Failure in Mitral Transcatheter Edge‐to‐Edge Repair Procedures
Background: Mitral transcatheter‐edge‐to‐edge‐repair (M‐TEER) is mostly done with using general anesthesia (GA). Limited data including specific risk factors exist for a deep sedation (DS) approach.Methods and Results: 464 M‐TEER procedures were included for comparison of a DS approach versus those who required a conversion to GA. Specific predefined risk factors were analyzed to identify those patients who might not benefit from a DS strategy by the need of conversion to GA. The conversion rate from DS to GA was 6.7% (n = 433 successful DS and n = 31 conversion to GA). Mean age was 80 years. Classical surgical risk scores did not show any significant difference between the two groups. Patients with DS had a higher procedural success rate (96.1% versus 80.1%; p < 0.001). The time on the intensive care unit (ICU) (3.9 h versus 126 h; p = 0.023) was shorter for patients with DS. Patients who were in the need for a conversion to GA had a lower 30‐day and 1‐year survival rate. A multivariate analysis for conversion to GA showed body mass index (p = 0.023), pre‐existing kidney failure (p < 0.001), obstructive sleep apnea syndrome (OSAS) (p = 0.031), systolic pulmonary pressure value (p = 0.013), and concomitant tricuspid regurgitation (p = 0.049) as risk factors.Conclusions: Using DS in M‐TEER is feasible with a low conversion rate to GA. In case of a conversion, the procedure is less successful regarding reduction of MR and more complications occurred with a lower survival rate up to 12 months. These data suggest that conversion from DS to GA is high risk. Therefore, we could identify different predictors for the need of a conversion to GA. However, our results could only be hypothesis‐generated and should be evaluated in a randomized study.
- 1 January 2024
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2024 (1)
Open AccessPredictors for Sedation Failure in Mitral Transcatheter Edge‐to‐Edge Repair Procedures
Background: Mitral transcatheter‐edge‐to‐edge‐repair (M‐TEER) is mostly done with using general anesthesia (GA). Limited data including specific risk factors exist for a deep sedation (DS) approach.Methods and Results: 464 M‐TEER procedures were included for comparison of a DS approach versus those who required a conversion to GA. Specific predefined risk factors were analyzed to identify those patients who might not benefit from a DS strategy by the need of conversion to GA. The conversion rate from DS to GA was 6.7% (n = 433 successful DS and n = 31 conversion to GA). Mean age was 80 years. Classical surgical risk scores did not show any significant difference between the two groups. Patients with DS had a higher procedural success rate (96.1% versus 80.1%; p < 0.001). The time on the intensive care unit (ICU) (3.9 h versus 126 h; p = 0.023) was shorter for patients with DS. Patients who were in the need for a conversion to GA had a lower 30‐day and 1‐year survival rate. A multivariate analysis for conversion to GA showed body mass index (p = 0.023), pre‐existing kidney failure (p < 0.001), obstructive sleep apnea syndrome (OSAS) (p = 0.031), systolic pulmonary pressure value (p = 0.013), and concomitant tricuspid regurgitation (p = 0.049) as risk factors.Conclusions: Using DS in M‐TEER is feasible with a low conversion rate to GA. In case of a conversion, the procedure is less successful regarding reduction of MR and more complications occurred with a lower survival rate up to 12 months. These data suggest that conversion from DS to GA is high risk. Therefore, we could identify different predictors for the need of a conversion to GA. However, our results could only be hypothesis‐generated and should be evaluated in a randomized study.
- 1 May 2021
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 33 (5) , E356-+
The ALSTER-TAVI All-Comers Registry: Procedural and 1-Year Clinical Outcomes of Balloon-Expandable vs Self-Expanding Contemporary TAVI Valves
We compared procedural and clinical outcome variables of the Sapien 3 balloon-expandable valve and the Evolut R/Pro self-expanding valve in an all-comers collective. from Journal of Invasive Cardiology.
- 1 May 2021
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 33 (5) , E356-+
The ALSTER-TAVI All-Comers Registry: Procedural and 1-Year Clinical Outcomes of Balloon-Expandable vs Self-Expanding Contemporary TAVI Valves
We compared procedural and clinical outcome variables of the Sapien 3 balloon-expandable valve and the Evolut R/Pro self-expanding valve in an all-comers collective. from Journal of Invasive Cardiology.